Urology
Volume 72, Issue 6 , Pages 1224-1228, December 2008

Prognostic Significance of Cancer Volume Involving Seminal Vesicles in Patients With pT3bpN0 Prostate Cancer

  • Shinya Yamamoto

      Affiliations

    • Department of Urology, Japanese Foundation for Cancer Research, Cancer Institute Hospital, Tokyo, Japan
    • Corresponding Author InformationReprint requests: Shinya Yamamoto, M.D., Ph.D., Department of Urology, Cancer Institute Hospital, 3-10-6, Ariake, Koto-ku, Tokyo 135-8550 Japan
  • ,
  • Satoru Kawakami

      Affiliations

    • Department of Urology, Japanese Foundation for Cancer Research, Cancer Institute Hospital, Tokyo, Japan
  • ,
  • Junji Yonese

      Affiliations

    • Department of Urology, Japanese Foundation for Cancer Research, Cancer Institute Hospital, Tokyo, Japan
  • ,
  • Yasuhisa Fujii

      Affiliations

    • Department of Urology, Japanese Foundation for Cancer Research, Cancer Institute Hospital, Tokyo, Japan
  • ,
  • Tetsuro Tsukamoto

      Affiliations

    • Department of Urology, Japanese Foundation for Cancer Research, Cancer Institute Hospital, Tokyo, Japan
  • ,
  • Yuhei Ohkubo

      Affiliations

    • Department of Urology, Japanese Foundation for Cancer Research, Cancer Institute Hospital, Tokyo, Japan
  • ,
  • Yoshinobu Komai

      Affiliations

    • Department of Urology, Japanese Foundation for Cancer Research, Cancer Institute Hospital, Tokyo, Japan
  • ,
  • Yuichi Ishikawa

      Affiliations

    • Department of Pathology, Japanese Foundation for Cancer Research, Cancer Institute Hospital, Tokyo, Japan
  • ,
  • Iwao Fukui

      Affiliations

    • Department of Urology, Japanese Foundation for Cancer Research, Cancer Institute Hospital, Tokyo, Japan

Received 1 April 2008; accepted 28 June 2008. published online 26 August 2008.

Objectives

To investigate the prognostic effect of the prostate cancer (PCa) volume involving the seminal vesicles (CVSVs) in the radical prostatectomy specimen from patients with Stage pT3bpN0 PCa.

Methods

We retrospectively reviewed the clinical records of 27 patients with Stage pT3bpN0 PCa who had undergone radical prostatectomy alone. We measured the CVSVs using a grid method on the glass slide under microscopic inspection and investigated the association of the CVSVs with clinicopathologic variables.

Results

Prostate-specific antigen (PSA) failure was confirmed in 11 of the 27 patients (41%) during a median follow-up of 34 months. The 3-year PSA failure-free survival rate was 48%. The median CVSVs was 1.14 cm3. On univariate analysis, a CVSVs of >1.63 cm3 was associated with positive surgical margins (P = .018), bilateral seminal vesicle involvement (P = .03), a long maximal tumor dimension (P = .031), and a greater preoperative PSA level (P = .0007). The 3-year PSA failure-free survival rate for those with a CVSVs of ≤1.63 cm3 vs >1.63 cm3 was 80% and 0%, respectively (P = .0009). On multivariate analysis, only the PSA level and CVSVs were identified as significant and independent predictors of PSA failure. Stratifying patients into 3 risk groups by these predictors, the PSA failure-free survival rate for patients with a PSA level ≥10 ng/mL and a CVSVs of >1.63 cm3 was significantly worse than for any other group.

Conclusions

The CVSVs is useful and invaluable as an independent predictor of PSA failure in patients with Stage pT3bpN0 PCa. The measurement of the CVSVs is simple and helped to determine the indication for adjuvant treatment after radical prostatectomy.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0090-4295(08)00849-2

doi:10.1016/j.urology.2008.06.055

Urology
Volume 72, Issue 6 , Pages 1224-1228, December 2008